@article{oai:repo.qst.go.jp:00057052,
 author = {Girard, F and Fukuda, Hiroshi and Yoshida, Katsuya and et.al and 福田 寛 and 吉田 勝哉},
 journal = {Recent Advances in Biomedical Imaging (International Congress Series ; no. 1127)},
 month = {},
 note = {Background. Although boron neutron capture therapy (BNCT) is a very promising technique for the treatment of tumors, it is very difficult to clearly evaluate the dose absorbed by the tumor. Magnetic resonance imaging on the other hand, is known to be sensitive to products such as Gadolinium-DTPA complexes, which induce a modification in the contrast of the images. A contrast agent which would combine the properties of Gd-DTPA with a boron group could therefore be considered as a very promising compound for the follow-up and the evaluation of the dose in tumors when BNCT is carried out.
 Methods. MR sagittal T1-weighted images have been acquired on tumor-bearing rats before and after the injection of the product, and also before and after injection of Gd-DTPA, classically used as a contrast agent in MRI.
 Results. The images obtained show an enhancement in the contrast as good as Gd-DTPA, and also that the product stays for a long time in tumors.
 Conclusion. This product is a promising agent for MRI studies and for BNCT. Toxicity should be carefully assessed.},
 pages = {201--207},
 title = {Rat tumor imaging with B-10 carborane gadolinium complex},
 year = {1997}
}